Identification of genes related to heart failure using global gene expression profiling of human failing myocardium

Biochemical and Biophysical Research Communications

Volumn 393, Issue 1, 2010, Pages 55-60

  Min, Kyung Duk ^a   Asakura, Masanori ^a   Liao, Yulin ^c   Nakamaru, Kenji ^d   Okazaki, Hidetoshi ^a   Takahashi, Tomoko ^d   Fujimoto, Kazunori ^d   Ito, Shin ^a   Takahashi, Ayako ^a   Asanuma, Hiroshi ^e   Yamazaki, Satoru ^b   Minamino, Tetsuo ^g   Sanada, Shoji ^a   Seguchi, Osamu ^a   Nakano, Atsushi ^a   Ando, Yosuke ^d   Otsuka, Toshiaki ^d   Furukawa, Hidehiko ^d   Isomura, Tadashi ^f   Takashima, Seiji ^g   Mochizuki, Naoki ^b   Kitakaze, Masafumi ^a   more..

^a Department of Cardiovascular Medicine ^*  (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d DAIICHI SANKYO CO   (Japan)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f Hayama Heart Center   (Japan)

^g OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

cDNA microarray; Clinical parameter; Gene expression; Heart failure

Indexed keywords

ADENOVIRUS VECTOR; G PROTEIN COUPLED RECEPTOR; ION CHANNEL;

ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; COMPUTER MODEL; DATA BASE; FEMALE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE TARGETING; GENETIC TRANSFECTION; GPR35 GENE; GPR37L1 GENE; HEART EJECTION FRACTION; HEART FAILURE; HEART MUSCLE; HEART WEIGHT; HUMAN; HUMAN CELL; HUMAN TISSUE; INFORMATION RETRIEVAL; LUNG ARTERY PRESSURE; MALE; MICROARRAY ANALYSIS; MMP23 GENE; MYLK3 GENE; NBC1 GENE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADENOVIRIDAE; AGED; ANIMALS; CELLS, CULTURED; FEMALE; GENE EXPRESSION PROFILING; HEART FAILURE; HUMANS; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MIDDLE AGED; MYOCARDIUM; MYOCYTES, CARDIAC; RATS;

ADENOVIRIDAE; MUS; RATTUS;

EID: 77549088355     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.01.076     Document Type: Article

References (18)

1. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators, N. Engl. J. Med. 325 (1991) 293-302.
2. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF), Lancet 353 (1999) 2001-2007.
3. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., and Shusterman N.H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N. Engl. J. Med. 334 (1996) 1349-1355
4. Yang J., Moravec C.S., Sussman M.A., DiPaola N.R., Fu D., Hawthorn L., Mitchell C.A., Young J.B., Francis G.S., McCarthy P.M., and Bond M. Decreased SLIM1 expression and increased gelsolin expression in failing human hearts measured by high-density oligonucleotide arrays. Circulation 102 (2000) 3046-3052
5. Barrans J.D., Allen P.D., Stamatiou D., Dzau V.J., and Liew C.C. Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray. Am. J. Pathol. 160 (2002) 2035-2043
6. Tan F.L., Moravec C.S., Li J., Apperson-Hansen C., McCarthy P.M., Young J.B., and Bond M. The gene expression fingerprint of human heart failure. Proc. Natl. Acad. Sci. USA 99 (2002) 11387-11392
7. Blaxall B.C., Tschannen-Moran B.M., Milano C.A., and Koch W.J. Differential gene expression and genomic patient stratification following left ventricular assist device support. J. Am. Coll. Cardiol. 41 (2003) 1096-1106
8. Hall J.L., Birks E.J., Grindle S., Cullen M.E., Barton P.J., Rider J.E., Lee S., Harwalker S., Mariash A., Adhikari N., Charles N.J., Felkin L.E., Polster S., George R.S., Miller L.W., and Yacoub M.H. Molecular signature of recovery following combination left ventricular assist device (LVAD) support and pharmacologic therapy. Eur. Heart J. 28 (2007) 613-627
9. Rysa J., Leskinen H., Ilves M., and Ruskoaho H. Distinct upregulation of extracellular matrix genes in transition from hypertrophy to hypertensive heart failure. Hypertension 45 (2005) 927-933
10. Kittleson M.M., Ye S.Q., Irizarry R.A., Minhas K.M., Edness G., Conte J.V., Parmigiani G., Miller L.W., Chen Y., Hall J.L., Garcia J.G., and Hare J.M. Identification of a gene expression profile that differentiates between ischemic and nonischemic cardiomyopathy. Circulation 110 (2004) 3444-3451
11. Barth A.S., Kuner R., Buness A., Ruschhaupt M., Merk S., Zwermann L., Kaab S., Kreuzer E., Steinbeck G., Mansmann U., Poustka A., Nabauer M., and Sultmann H. Identification of a common gene expression signature in dilated cardiomyopathy across independent microarray studies. J. Am. Coll. Cardiol. 48 (2006) 1610-1617
12. Asakura M., and Kitakaze M. Global gene expression profiling in the failing myocardium. Circ. J. 73 (2009) 1568-1576
13. Seguchi O., Takashima S., Yamazaki S., Asakura M., Asano Y., Shintani Y., Wakeno M., Minamino T., Kondo H., Furukawa H., Nakamaru K., Naito A., Takahashi T., Ohtsuka T., Kawakami K., Isomura T., Kitamura S., Tomoike H., Mochizuki N., and Kitakaze M. A cardiac myosin light chain kinase regulates sarcomere assembly in the vertebrate heart. J. Clin. Invest. 117 (2007) 2812-2824
14. Asakura M., Kitakaze M., Takashima S., Liao Y., Ishikura F., Yoshinaka T., Ohmoto H., Node K., Yoshino K., Ishiguro H., Asanuma H., Sanada S., Matsumura Y., Takeda H., Beppu S., Tada M., Hori M., and Higashiyama S. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat. Med. 8 (2002) 35-40
15. Chan J.Y., Takeda M., Briggs L.E., Graham M.L., Lu J.T., Horikoshi N., Weinberg E.O., Aoki H., Sato N., Chien K.R., and Kasahara H. Identification of cardiac-specific myosin light chain kinase. Circ. Res. 102 (2008) 571-580
16. Wang J., Simonavicius N., Wu X., Swaminath G., Reagan J., Tian H., and Ling L. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J. Biol. Chem. 281 (2006) 22021-22028
17. Taniguchi Y., Tonai-Kachi H., and Shinjo K. Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35. FEBS Lett. 580 (2006) 5003-5008
18. Taniguchi Y., Tonai-Kachi H., and Shinjo K. 5-Nitro-2-(3-phenylpropylamino)benzoic acid is a GPR35 agonist. Pharmacology 82 (2008) 245-249